Stocks and Investing
Stocks and Investing
Fri, December 3, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, December 2, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Andrew Fein Maintained (VRTX) at Strong Buy and Held Target at $275 on, Dec 2nd, 2021
Andrew Fein of HC Wainwright & Co., Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Strong Buy and Held Target at $275 on, Dec 2nd, 2021.
Andrew has made no other calls on VRTX in the last 4 months.
There are 6 other peers that have a rating on VRTX. Out of the 6 peers that are also analyzing VRTX, 3 agree with Andrew's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Do Kim of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $218 on, Friday, November 19th, 2021
- Evan Seigerman of "BMO Capital" Initiated at Hold and Held Target at $202 on, Friday, November 19th, 2021
- Paul Matteis of "Stifel" Downgraded from Strong Buy to Hold and Decreased Target to $213 on, Thursday, September 9th, 2021
These are the ratings of the 3 analyists that currently disagree with Andrew
- Debjit Chattopadhyay of "Guggenheim" Maintained at Strong Buy with Increased Target to $286 on, Wednesday, December 1st, 2021
- Robyn Karnauskas of "Truist Securities" Maintained at Strong Buy with Increased Target to $341 on, Wednesday, December 1st, 2021
- Matthew Harrison of "Morgan Stanley" Downgraded from Hold to Sell and Held Target at $202 on, Tuesday, September 7th, 2021
Contributing Sources